FGFR2 and cholangiocarcinoma: This oral agent with potent pan-FGFR activity showed an overall response rate of 20.7% and disease control rate of 82.8%.16 Altogether, these clinical responses toward FGFR inhibitors suggest that certain FGFR alterations, particularly FGFR2 fusions, may serve as biomarkers for personalized CCA therapy.